SCHEMBL18769746

SCHEMBL18769746

COCc1ccc2c(c1)C#Cc1ccccc1C(OC(=O)NCCCCCC(=O)OC)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
KMT2A Q03164 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12288689 0.89 LMNA (0.41) LMNAKMT2AHDAC3HDAC4HDAC1
SCHEMBL12285877 0.80 HDAC3 (0.40) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL18501063 0.79 KMT2A (0.39) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL12286069 0.79 KMT2A (0.48) LMNAKMT2AHDAC3HDAC4HDAC1
SCHEMBL16895236 0.76 DRD3 (0.38) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL10283653 0.76 HDAC3 (0.40) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL10295062 0.75 DRD3 (0.40) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL12285327 0.75 CYP3A4 (0.36) LMNAALDH1A1CYP3A4MAPTSMN1; SMN2
SCHEMBL18588545 0.74 HTT (0.40)
SCHEMBL12288686 0.73 EPHX2 (0.35) LMNANAMPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550386-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) ALNYLAM PHARMACEUTICALS, INC. (US) 2020-02-04 US disclosed
US-20170107513-A1 MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) BANK OF AMERICA, N.A. 2017-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550386-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) FANCI, PCNA, DNMT1 LMNA 3819/4885KMT2A 1140/4885HDAC3 4036/4885
US-20170107513-A1 MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) FANCI, PCNA, DNMT1 LMNA 3819/4885KMT2A 1140/4885HDAC3 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.